Legend Biotech (LEGN)
(Real Time Quote from BATS)
$46.03 USD
+0.73 (1.61%)
Updated Apr 29, 2024 11:52 AM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Legend Biotech Corporation Sponsored ADR (LEGN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$85.65 | $94.00 | $65.00 | 89.07% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for Legend Biotech Corporation Sponsored ADR comes to $85.65. The forecasts range from a low of $65.00 to a high of $94.00. The average price target represents an increase of 89.07% from the last closing price of $45.30.
Analyst Price Targets (14)
Broker Rating
Legend Biotech Corporation Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 18 brokerage firms. The current ABR compares to an ABR of 1.44 a month ago based on 18 recommendations.
Of the 18 recommendations deriving the current ABR, 14 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 77.78% and 11.11% of all recommendations. A month ago, Strong Buy made up 72.22%, while Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 14 | 14 | 13 | 13 | 13 |
Buy | 2 | 2 | 2 | 1 | 1 |
Hold | 2 | 2 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.44 | 1.41 | 1.41 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/17/2024 | Scotiabank | George Farmer | Hold | Strong Buy |
4/8/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
4/4/2024 | Cantor Fitzgerald & Co | Rick Bienkowski | Not Available | Strong Buy |
3/13/2024 | Raymond James | Sean Mccutcheon | Moderate Buy | Moderate Buy |
3/1/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
2/23/2024 | William Blair | Sami Corwin | Hold | Hold |
2/6/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Justin R Zelin | Strong Buy | Strong Buy |
1/2/2024 | Guggenheim Securities | Michael Schmidt | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 18 |
Average Target Price | $85.65 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.24 |